ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SYNC Syncona Limited

123.00
0.20 (0.16%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.16% 123.00 122.20 122.80 124.00 122.20 122.60 632,316 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.55 814.75M

Syncona Limited Autolus commences clinical trial programmes

18/09/2017 7:00am

UK Regulatory


 
TIDMSYNC 
 
Syncona Limited 
 
                  Autolus commences clinical trial programmes 
 
18 September 2017 
 
Syncona Ltd ("Syncona"), a leading healthcare company focused on investing in 
and building global leaders in life science, today notes that its portfolio 
company, Autolus, which is developing and commercialising next-generation 
engineered T-cell therapies to combat cancer, has announced the commencement of 
three clinical trials in its two lead programmes, AUTO2 and AUTO3. 
 
In its AUTO2 APRIL study in multiple myeloma, Autolus has announced the 
initiation and completion of the first dose cohort of its Phase I/II study of 
its dual-targeted Chimeric Antigen Receptor (CAR) T cell therapy in patients 
with relapsed/refractory multiple myeloma. AUTO2 is the first dual targeting 
CAR-T cell therapy in clinical development for the treatment of multiple 
myeloma. 
 
Autolus has also initiated its AUTO3 programme with two Phase I/II studies, 
AMELIA in pediatric Acute Lymphoblastic Leukaemia and ALEXANDER in adult 
Diffuse Large B Cell Lymphoma. AUTO3 is the first dual targeting CAR T cell 
therapy to enter clinical studies targeting CD19 and CD22 with 
independently-acting CARs. 
 
[ENDS] 
 
Enquiries 
 
Syncona Ltd 
Siobhan Weaver 
Tel: +44 (0) 20 7611 2031 
 
 
Tulchan Communications 
Martin Robinson 
Lisa Jarrett-Kerr 
Tel: +44 (0) 207 353 4200 
 
Copies of this press release and other corporate information can be found on 
the company website at: www.synconaltd.com 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments.  We seek to partner with the best, brightest 
and most ambitious minds in science to build globally competitive businesses. 
We are established leaders in gene therapy, cell therapy and advanced 
diagnostics, and focus on delivering dramatic efficacy for patients in areas of 
high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
About Autolus: 
 
Autolus is a clinical-stage, biopharmaceutical company, focused on the 
development and commercialisation of engineered T-cell immunotherapy products 
to combat cancer. Building on its advanced cell programming and manufacturing 
technologies, Autolus has developed a pipeline of product candidates for the 
treatment of both haematological malignancies and solid tumours. For further 
information please visit the Company's website at: www.autolus.com 
 
About AUTO2 and the APRIL study: 
 
AUTO2 is a chimeric antigen receptor T cell (CAR-T cell) therapy that targets 
both B cell maturation antigen (BCMA) and transmembrane activator and calcium 
modulator and cyclophilin ligand interactor (TACI). By targeting TACI in 
addition to BCMA on the same cancer cell, more patients may be eligible for 
CAR-T treatment and less patients may be at risk of cancer relapse due to loss 
of BCMA expression on their cancer. In addition, AUTO2 also carries an RQR8 
safety switch which allows the T cells to be removed with a single high dose of 
rituximab. 
 
The APRIL Study is a single-arm, open-label, multi-centre, Phase I/II Study 
evaluating the safety and clinical activity of AUTO2, a CAR-T Cell Treatment 
Targeting BCMA and TACI, in patients with relapsed or refractory multiple 
myeloma. In the dose-escalation phase I/II study cohorts of patients will 
receive ascending doses of AUTO2 to determine the maximum tolerated dose and 
establish a recommended dose. The second part of the study is an expansion 
phase where patients will receive AUTO2 to further evaluate the safety, 
tolerability and clinical activity at this recommended dose. 
 
Multiple myeloma is a type of blood cancer that affects the plasma cells and is 
the second most commonly diagnosed blood cancer, after non-Hodgkin lymphoma. 
There are a number of approved therapies to treat the disease but there is 
currently no cure. 
 
About AUTO3 and the AMELIA and ALEXANDER studies: 
 
AUTO3 is an autologous T cell product, genetically modified to express two 
separate chimeric antigen receptors (CARs) which recognise CD19 and CD22, two 
antigens expressed by cancer cells in B cell leukaemia and lymphoma. AUTO3 is 
designed to minimize the risk of relapse due to antigen loss, a key mechanism 
of resistance shown in single antigen targeting CAR-T therapies. 
 
The AMELIA study is is a single?arm, open-label, multi-centre, phase I/II study 
evaluating the safety and clinical activity of AUTO3 in paediatric and young 
adult patients with relapsed or refractory B Cell Acute Lymphoblastic Leukaemia 
(ALL). The ALEXANDER Study is a Phase I/II, open-label, multi-centre study to 
evaluate the safety and efficacy of AUTO3 administered by intravenous infusion 
in adult Diffuse Large B Cell Lymphoma (DLBCL) patients. The studies are 
dose-escalation phase I/II trials in which cohorts of patients will receive 
ascending doses of AUTO3 to determine the maximum tolerated dose and establish 
a recommended dose. The second part of the study is an expansion phase where 
patients will receive AUTO3 to further evaluate the safety, tolerability and 
clinical activity at this recommended dose. In addition to the effects of AUTO3 
alone, combination with short-duration use of a checkpoint inhibitor is also 
being evaluated in the ALEXANDER Study. 
 
ALL is a cancer of the bone marrow and blood, in which the body makes abnormal 
white blood cells (lymphocytes). The disease progresses quickly and is the most 
common childhood cancer in the U.S and EU. DLBCL is an aggressive type of 
non-Hodgkin lymphoma (NHL) that develops from the B cells in the lymphatic 
system. It is a rapidly growing blood cancer, which can occur in lymph nodes or 
outside of the lymphatic system, in the brain, bone, breast, skin, thyroid, 
gastrointestinal tract, and testes. 
 
About CAR-T therapy: 
 
CAR-T therapy involves re-programming a patient's immune system to kill tumour 
cells. T-cells, a type of white blood cell, are extracted from a patient's 
blood, manipulated outside the body to incorporate the CAR gene, and then 
returned to the patient by infusion. The CAR gene introduces a targeting 
mechanism to the T-cells, enabling them to recognise, engage and destroy tumour 
cells in a highly specific manner. Clinical trials of CAR T-cells in multiple 
myeloma and B-cell malignancies, including non-Hodgkin lymphoma, suggest that 
this approach may transform treatment of cancer patients, many of whom have no 
other therapeutic options. 
 
 
 
END 
 

(END) Dow Jones Newswires

September 18, 2017 02:00 ET (06:00 GMT)

1 Year Syncona Chart

1 Year Syncona Chart

1 Month Syncona Chart

1 Month Syncona Chart

Your Recent History

Delayed Upgrade Clock